Azacitidine - Pfizer

Drug Profile

Azacitidine - Pfizer

Alternative Names: 5-azacytidine; Aza-C; Azacytidine; CC-486; Ladakamycin; NS-17; NSC-102816; U-18496; VIDAZA; Vidaza

Latest Information Update: 18 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmacia Corporation
  • Developer Australasian Leukaemia & Lymphoma Group; Celgene Corporation; Columbia University; H. Lee Moffitt Cancer Center and Research Institute; Karolinska University Hospital; Kirby Institute for infection and immunity in society; Nippon Shinyaku; Pfizer; University Hospital Regensburg; University of Bologna; University of Colorado at Denver; University of Kansas Medical Center; University of Leipzig; University of Texas M. D. Anderson Cancer Center; University of Utah; Washington University School of Medicine; Weill Cornell Medical College
  • Class Antineoplastics; Aza compounds; Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase II Breast cancer; Graft-versus-host disease; Leukaemia; Nasopharyngeal cancer; Non-small cell lung cancer; Peripheral T-cell lymphoma
  • Phase I/II Colorectal cancer; Diffuse large B cell lymphoma; Renal cancer; Solid tumours
  • No development reported Lymphoma; Multiple myeloma

Most Recent Events

  • 12 Oct 2018 Celgene plans a phase III trial for T cell lymphoma in Japan (PO) (NCT03703375)
  • 28 Aug 2018 University of Pittsburgh, Incyte Corporation and Merck Sharp & Dohme withdraws a phase Ib/II trial for Colorectal cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) prior to enrolment in the USA(NCT03182894)
  • 18 Jun 2018 Phase-II clinical trials in Chronic myelomonocytic leukaemia in Australia (PO) (NCT03493646)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top